People · Operator
Named in public records as an officer, director or promoter · active 2022–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ArriVent Biopharma, Inc. | — | Biotechnology | Series D+ | $260.0M | $2.0B | 2022 |
| Immunocore Holdings plc | — | Biotechnology | Series D+ | $140.0M | $2.9B | 2022 |
| Outpace Bio, Inc. | — | Biotechnology | Series C | $56.0M | $491.3M | 2024 |
Bahija Jallal at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bahija Jallal on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| James Healy | 1 | 8 |
| David Berman | 1 | 8 |
| Jake Simson | 1 | 6 |
| Vasudev Bailey | 1 | 5 |
| John Bell | 1 | 5 |
| Robert Perez | 1 | 3 |
| Jason Zhang | 1 | 3 |
| Kristine Peterson | 1 | 3 |
| Travis Coy | 1 | 2 |
| Zhengbin (Bing) Yao | 1 | 2 |
| Siddharth Kaul | 1 | 1 |
| Roy Herbst | 1 | 1 |
| Aaron Foster | 1 | 1 |
| Charity Scripture | 1 | 1 |
| Scott Boyken | 1 | 1 |
| Eric Soller | 1 | 1 |
| Marc Lajoie | 1 | 1 |
| Stuart Lutzker | 1 | 1 |
| Cong Xu | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.